Invivyd, Inc. (NASDAQ:IVVD – Get Rating) – Equities researchers at Jefferies Financial Group issued their Q1 2023 earnings per share estimates for Invivyd in a report released on Friday, November 11th. Jefferies Financial Group analyst M. Yee anticipates that the company will earn ($0.42) per share for the quarter. The consensus estimate for Invivyd’s current full-year earnings is ($2.37) per share. Jefferies Financial Group also issued estimates for Invivyd’s Q2 2023 earnings at ($0.45) EPS, Q3 2023 earnings at ($0.43) EPS and Q4 2023 earnings at ($0.46) EPS.
Separately, Morgan Stanley assumed coverage on shares of Invivyd in a research note on Wednesday, September 14th. They issued an “underweight” rating and a $3.00 target price on the stock.
Invivyd Stock Performance
Invivyd, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
- Get a free copy of the StockNews.com research report on Invivyd (IVVD)
- Alphabet Stock Offers a Rare Buying Opportunity
- Walt Disney Stock is Set to Reset Expectations
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- S&P 500 Component DexCom Set For Further Price, Earnings Growth
- MarketBeat: Week in Review 11/7 – 11/11
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.